Skip to main content
ADIL
NASDAQ Life Sciences

Director Buys $100K in Pre-funded Warrants Following Azora Therapeutics Merger

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.7
Mkt Cap
$6.109M
52W Low
$1.31
52W High
$18.9
52W Position info
106% above low
Off High info
86% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

ADIL has more than doubled off its 52-week low of $1.31.

Summary

A director at Adial Pharmaceuticals purchased nearly $100,000 in pre-funded warrants, signaling strong conviction after the company's recent reverse merger and financing deal.


Key Events · Ownership and Investor Activity · ADIL

  • Director Purchase

    Director Wendy B. Young acquired $99,999 worth of pre-funded warrants on June 12, 2026, at a price of $2.75 per unit.

  • Significant Stake

    This purchase represents a substantial investment, equivalent to 1.637% of the company's current market capitalization.

  • Post-Merger Confidence

    The transaction follows the company's recent reverse merger with Azora Therapeutics and a new financing deal, which provides significant capital and addresses prior going concern warnings.


Analysis · ADIL · Life Sciences

A director's significant purchase of pre-funded warrants, equivalent to 1.6% of the company's market capitalization, indicates strong confidence in the company's future. This transaction occurred immediately after the company announced a reverse merger with Azora Therapeutics and secured substantial financing, which addresses previous going concern warnings and provides a longer cash runway.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 47.7% of the 1624 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ADIL was trading at $2.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.1M. The 52-week trading range was $1.31 to $18.90. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ADIL - Latest Insights

ADIL
Nov 09, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 5:56 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $5.08
Real-time Price: $4.86 info
Change: -$0.220 (-4%) info
Market Cap: $13.261M info
ADIL
Oct 28, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: -$0.0036 (-0.07%) info
Market Cap: $13.261M info
ADIL
Oct 20, 2026, 8:25 PM EDT
Filing Type: 10-Q/A
Importance Score:
8
Price at Filing: $3.79
Real-time Price: $4.86 info
Change: +$1.07 (+28%) info
Market Cap: $13.261M info
ADIL
Sep 18, 2026, 5:18 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Price at Filing: $4.86
Real-time Price: $4.86 info
Change: $0 (0%) info
Market Cap: $13.261M info